Bora Biologics Achieves 2,000L Scale-Up Milestone in US
San Diego, California, USA, April 6, 2026 Commercial-Scale Manufacturing Readiness Demonstrated In a significant advancement for biologics manufacturing and...
biologics development
Advertisement
Trimmune JV Financing Fuels Next-Gen Immunotherapy Development
MIRAMAR, Fla., Feb. 16, 2026 — Clinical-stage immunotherapy innovator HCW Biologics and recombinant biologics developer WY Biotech have closed...
Nektar Raises $460M to Advance Immunotherapy Pipeline
SAN FRANCISCO, Feb. 13, 2026 — Nektar Therapeutics announced the successful closing of a $460 million underwritten public offering,...
Zenocutuzumab Gains FDA Orphan Drug Status in CCA
WALTHAM, Mass., Feb. 2026 — Partner Therapeutics announced that zenocutuzumab-zbco, an investigational bispecific antibody therapy, has received U.S. FDA...
Third Arc Bio Secures $52M to Advance Antibody Pipeline
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
Advertisements
Alvotech Strengthens Biosimilar Growth With $100M Financing
REYKJAVÍK, ICELAND | December 31, 2025 — Alvotech announced it has secured a USD 100 million senior term loan...
Rentschler & Coriolis Form Integrated CDMO Partnership for Biologics
Laupheim and Martinsried, Germany, December 2, 2025 — Rentschler Biopharma, a global contract development and manufacturing organization, and Coriolis...
Tectonic Therapeutic Highlights GPCR Program at Investor Events
Watertown, Mass. — December 1, 2025 — Tectonic Therapeutic, Inc. announced that its executive leadership will participate in two...
Zenas BioPharma Showcases Autoimmune Advances at Q4 2025 Events
Dateline — WALTHAM, Mass., November 11, 2025:Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing...
Advertisement
